Policy options for deploying anti-malarial drugs in endemic countries: A population genetics approach

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Antao, Tiago ^a,b   Hastings, Ian ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adherence; Drugs; Malaria; Plasmodium falciparum; Policy; Resistance; Treatment

Indexed keywords

ANTIMALARIAL AGENT;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; DRUG USE; ENDEMIC DISEASE; GENE LINKAGE DISEQUILIBRIUM; GENETIC MODEL; HEALTH CARE POLICY; HOST PARASITE INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MOLECULAR DYNAMICS; MULTIPLE FIRST LINE THERAPY; POPULATION GENETICS; PREVALENCE;

ANTIMALARIALS; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; ENDEMIC DISEASES; EPISTASIS, GENETIC; GENETICS, POPULATION; HEALTH POLICY; HUMANS; LINKAGE DISEQUILIBRIUM; MALARIA; MODELS, GENETIC; PLASMODIUM;

EID: 84871004355     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-422     Document Type: Article

References (46)

1. Increasing malaria hospital admissions in Uganda between 1999 and 2009. Okiro EA, Bitira D, Mbabazi G, Mpimbaza A, Alegana VA, Talisuna AO, Snow RW, BMC Med 2011 9 37 10.1186/1741-7015-9-37 21486498
2. The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Russel S, Am J Trop Med Hyg 2004 71 147 155 15331831 (Pubitemid 39121316)
3. WHO, the Global Fund, and medical malpractice in malaria treatment. Attaran A, Barnes KI, Curtis C, D'Alessandro U, Fanello CI, Galinski MR, Kokwaro G, Looareesuwan S, Makanga M, Mutabingwa TK, Talisuna A, Trape JF, Watkins WM, Lancet 2004 363 237 240 10.1016/S0140-6736(03)15330-5 14738799 (Pubitemid 38114725)
4. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Bosman A, Mendis KN, Am J Trop Med Hyg 2007 77 193 197 18165492
5. How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance. Hastings IM, Trends Parasitol 2011 27 67 72 10.1016/j.pt.2010.09.005 20971040
6. Return of chloroquine antimalarial efficacy in Malawi. Laufer M, Thesing P, Eddington N, Masonga R, Dzinjalamala F, Takala S, Taylor T, Plowe C, N Engl J Med 2006 355 1959 1966 10.1056/NEJMoa062032 17093247 (Pubitemid 44708015)
7. World Health Organization, Guidelines for the treatment of malaria Geneva, Switzerland: World Health Organization 2 2010
8. Antimalarial drug quality in the most severely malarious parts of Africa-a six country study. Bate R, Coticelli P, Tren R, Attaran A, PLoS One 2008 3 2132 10.1371/journal.pone.0002132 18461128 (Pubitemid 352025174)
9. Benefits of using multiple first-line therapies against malaria. Boni MF, Smith DL, Laxminarayan R, Proc Natl Acad Sci USA 2008 105 14216 14221 10.1073/pnas.0804628105 18780786
10. "Clonal" population structure of the malaria agent Plasmodium falciparum in high-infection regions. Razakandrainibe FG, Durand P, Koella JC, De Meeus T, Rousset F, Ayala FJ, Renaud F, Proc Natl Acad Sci USA 2005 102 17388 17393 10.1073/pnas.0508871102 16301534 (Pubitemid 41740876)
11. Sexual» population structure and genetics of the malaria agent P. falciparum. Mzilahowa T, McCall PJ, Hastings IM, PLoS One 2007 2 613 10.1371/journal.pone.0000613 17637829 (Pubitemid 351308739)
12. Multigenic drug resistance among inbred malaria parasites. Dye C, Williams BG, Proc R Soc Lond, Ser B Biol Sci 1997 264 61 67 10.1098/rspb.1997. 0009 (Pubitemid 27067931)
13. Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria. Antao T, Hastings IM, Proc R Soc Lond, Ser B Biol Sci 2011 278 1705 1712 10.1098/rspb.2010.1907
14. Modelling a predictable disaster: The rise and spread of drug-resistant malaria. Hastings IM, D'Alessandro U, Parasitol Today 2000 16 340 347 10.1016/S0169-4758(00)01707-5 10900482 (Pubitemid 30460031)
15. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Wargo AR, Huijben S, de Roode JC, Shepherd J, Read AF, Proc Natl Acad Sci USA 2007 104 19914 19919 10.1073/pnas.0707766104 18056635
16. Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: Indication of drug pressure. Hodel EM, Genton B, Zanolari B, Mercier T, Duong S, Beck HP, Olliaro P, Decosterd LA, Ariey F, J Infect Dis 2010 202 1088 1094 10.1086/655779 20726764
17. Residual antimalarials in malaria patients from Tanzania-implications on drug efficacy assessment and spread of parasite resistance. Hodel EM, Kabanywanyi AM, Malila A, Zanolari B, Mercier T, Beck HP, Buclin T, Olliaro P, Decosterd LA, Genton B, PLoS One 2009 4 12
18. Global incidence of multidrug-resistant tuberculosis. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, Williams BG, Dye C, J Infect Dis 2006 194 479 485 10.1086/505877 16845631 (Pubitemid 44162659)
19. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG, Proc Natl Acad Sci USA 2002 99 7687 7692 10.1073/pnas.122108599 12032344 (Pubitemid 34568752)
20. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Kollef MH, Clin Infect Dis 2006 43 82 S88 10.1086/504484 16894520 (Pubitemid 44267145)
21. Antibiotic cycling versus mixing: The difficulty of using mathematical models to definitively quantify their relative merits. Beardmore RE, Peña-Miller R, Math Biosci Eng 2010 7 923 933 21077716
22. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Bergstrom CT, Lo M, Lipsitch M, Proc Natl Acad Sci USA 2004 101 13285 13290 10.1073/pnas.0402298101 15308772 (Pubitemid 39209657)
23. Complex dynamics and stability of antimalarial drug resistance. Hastings IM, Parasitology 2006 132 615 624 16426485
24. ogaraK: a population genetics simulator for malaria. Antao T, Hastings IM, Bioinformatics 2011 27 1335 1336 10.1093/bioinformatics/btr139 21414984
25. Unstable malaria in Sudan: the influence of the dry season. Clone multiplicity of Plasmodium falciparum infections in individuals exposed to variable levels of disease transmission. Arnot D, Trans R Soc Trop Med Hyg 1998 92 580 585 10.1016/S0035-9203(98)90773-8 10326095 (Pubitemid 29015203)
26. Close kinship within multiple-genotype malaria parasite infections. Nkhoma SC, Nair S, Cheeseman IH, Rohr-Allegrini C, Singlam S, Nosten F, Anderson TJC, Proc R Soc Lond, Ser B Biol Sci 2012 279 2589 2598 10.1098/rspb.2012.0113
27. Microsatellite markers reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. Anderson TJC, Haubold B, Williams JT, Estrada-Franco JG, Richardson L, Mollinedo R, Bockarie M, Mokili J, Mharakurwa S, French N, Whitworth J, Velez ID, Brockman AH, Nosten F, Ferreira MU, Day KP, Mol Biol Evol 2000 17 1467 1482 10.1093/oxfordjournals.molbev.a026247 11018154
28. Field-based evidence for linkage of mutations associated with chloroquine (PfCRT/PfMDR1) and sulfadoxine-pyrimethamine (PfDHFR/PfDHPS) resistance and for the fitness cost of multiple mutations in P. falciparum. Osman ME, Mockenhaupt FP, Bienzle U, Elbashir MI, Giha HA, Infect Genet Evol 2007 7 52 59 10.1016/j.meegid.2006.03.008 16690361 (Pubitemid 44858293)
29. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S, Lancet 2004 364 438 447 10.1016/S0140-6736(04)16767-6 15288742 (Pubitemid 39036891)
30. Probability of emergence of antimalarial resistance in different stages of the parasite life cycle. Pongtavornpinyo W, Hastings IM, Dondorp A, White LJ, Maude RJ, Saralamba S, Day NP, White NJ, Boni MF, Evol Appl 2009 2 52 61 10.1111/j.1752-4571.2008.00067.x 20526409
31. Artemisinin resistance in Plasmodium falciparum malaria. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ, N Engl J Med 2009 361 455 467 10.1056/NEJMoa0808859 19641202
32. Intercontinental spread of pyrimethamine-resistant malaria. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T, Science 2004 305 1124 10.1126/science.1098876 15326348 (Pubitemid 39100317)
33. Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug deployment policies. Babiker H, Hastings IM, Swedberg G, Expert Rev Anti-infe 2009 7 581 593 10.1586/eri.09.29
34. Protecting the malaria drug arsenal: halting the rise and spread of amodiaquine resistance by monitoring the PfCRT SVMNT type. Sa JM, Twu O, Malaria J 2010 9 374 10.1186/1475-2875-9-374
35. The evolution of drug resistant malaria; the role of drug elimination half-life. Hastings IM, Watkins WM, White NJ, Philos Trans R Soc London [Biol] 2002 357 505 519 10.1098/rstb.2001.1036 (Pubitemid 34489862)
36. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. Sisowath C, Petersen I, Veiga MI, Mårtensson A, Premji Z, Björkman A, Fidock DA, Gil JP, J Infect Dis 2009 199 750 757 10.1086/596738 19210165
37. Polymorphisms within PfMDR1 alter the substrate specificity for anti-malarial drugs in Plasmodium falciparum. Sanchez CP, Rotmann A, Stein WD, Lanzer M, Mol Microbiol 2008 70 786 798 18713316
38. Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Mu J, Myers RA, Jiang H, Liu S, Ricklefs S, Waisberg M, Chotivanich K, Wilairatana P, Krudsood S, White NJ, Udomsangpetch R, Cui L, Ho M, Ou F, Li H, Song J, Li G, Wang X, Seila S, Sokunthea S, Socheat D, Sturdevant DE, Porcella SF, Fairhurst RM, Wellems TE, Awadalla P, Su XZ, Nat Genet 2010 42 268 271 10.1038/ng.528 20101240
39. The origins and spread of antimalarial drug resistance: Lessons for policy makers. Anderson TJC, Roper C, Acta Trop 2005 94 269 280 10.1016/j.actatropica.2005.04.010 15878153 (Pubitemid 40720332)
40. Quantifying the evolution and impact of antimalarial drug resistance: drug use, spread of resistance and drug failure over a 12 year period in Papua New Guinea. Nsanzabana C, Hastings IM, Marfurt J, Muller I, Baea K, Rare L, Schapira A, Felger I, Betschart B, Smith TA, Beck HP, Genton B, J Infect Dis 2010 201 435 443 10.1086/649784 20047502
41. Epidemiological models for the spread of anti-malarial resistance. Koella JC, Antia R, Malar J 2003 2 3 10.1186/1475-2875-2-3 12643812
42. Immunity to malaria: more questions than answers. Langhorne J, Ndungu FM, Sponaas A-M, Marsh K, Nat Immunol 2008 9 725 732 18563083 (Pubitemid 351859155)
43. Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. Rogerson SJ, Wijesinghe RS, Meshnick SR, Lancet Infect Dis 2010 10 51 59 10.1016/S1473-3099(09)70322-6 20129149
44. Evolutionary parasitology applied to control and elimination policies. Antao T, Trends Parasitol 2011 27 233 234 10.1016/j.pt.2011.03.004 21497137
45. Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Smith D, Klein E, McKenzie FE, Laxminarayan R, Malar J 2010 9 217 10.1186/1475-2875-9-217 20653960
46. The origins of antimalarial drug resistance. Hastings IM, Trends Parasitol 2004 20 512 518 10.1016/j.pt.2004.08.006 15471702 (Pubitemid 39313089)